AvantGuard is developing Avantamine™, a patented antimicrobial platform that enhances biocompatible chemistry to provide broad-spectrum, long-lasting protection against bacteria, fungi, and viruses without contributing to antimicrobial resistance. The company’s product portfolio includes AvantSept, AvantGel, and Avant24, targeting indications from ringworm to MRSA and applications across skin, mucosa, wounds, and surfaces. Target markets include infection prevention, wound care, dermatology, and healthcare environments, as well as defense and transportation. AvantGuard has been supported by more than $9 million in NIH, NSF, and federal grant funding and states its platform can be incorporated into products representing over $60 billion in annual sales. The company is moving from scientific validation toward manufacturing readiness by establishing cGMP manufacturing capabilities for its monomer and polymer components. AvantGuard is a Cornell University spin-off and IndieBio alum founded in Ithaca, New York.

Total raised

$7M

Funding rounds

3

Latest round

Seed

Latest activity

Jun 2026